OmniMSC-AMI

Phase 1Biologic

TTaiwan Bio Therapeutics Inc.

OmniMSC-AMI is one of 43 biologic programs targeting Myocardial Infarction. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myocardial InfarctionActive, not recruiting

Safety IssuesTerminated

Myocardial InfarctionPhase 1

Active, not recruiting

Safety IssuesPhase 1

Terminated

Competition

Competitive Landscape

232 competitors in Myocardial Infarction

#DrugCompanyPhaseTrials

Ikorel

Merck & Co.

Phase 3

2 2

Ozempic

Novo Nordisk

Phase 3

2 3

Medrol

Pfizer

Phase 3

2 4

Lovenox

Sanofi

Phase 3

1 5

Aranesp

Reopro

4 7

Zetia

OOrganon and Co

Phase 3

3 8

Jardiance

Boehringer Ingelheim

Phase 3

2 9

PROCRIT

WWim Janssens

Phase 3

1 10

Tekturna

Tibotec Pharmaceuticals, Ireland

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety Issues1 trial

Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.

Terminated·TTaiwan Bio Therapeutics Inc.·Phase 1·NCT05724576·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OmniMSC-AMI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OmniMSC-AMI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OmniMSC-AMI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taiwan Bio Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TTaiwan Bio Therapeutics Inc.

OmniMSC-AMI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety Issues1 trial

References

Drug Info

Quick Facts

Related News